Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptinyx Inc.

0.0960
0.0000
Volume:- -
Turnover:- -
Market Cap:6.50M
PE:-0.10
High:0.0960
Open:0.0960
Low:0.0960
Close:0.0960
Loading ...

Company Profile

Company Name:
Aptinyx Inc.
Exchange:
EXPERT
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.